Navigating metabolic pathways to enhance antitumour immunity and immunotherapy.

Détails

ID Serval
serval:BIB_F7C5AE601718
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Navigating metabolic pathways to enhance antitumour immunity and immunotherapy.
Périodique
Nature reviews. Clinical oncology
Auteur⸱e⸱s
Li X., Wenes M., Romero P., Huang S.C., Fendt S.M., Ho P.C.
ISSN
1759-4782 (Electronic)
ISSN-L
1759-4774
Statut éditorial
Publié
Date de publication
07/2019
Peer-reviewed
Oui
Volume
16
Numéro
7
Pages
425-441
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Résumé
The development of immunotherapies over the past decade has resulted in a paradigm shift in the treatment of cancer. However, the majority of patients do not benefit from immunotherapy, presumably owing to insufficient reprogramming of the immunosuppressive tumour microenvironment (TME) and thus limited reinvigoration of antitumour immunity. Various metabolic machineries and nutrient-sensing mechanisms orchestrate the behaviour of immune cells in response to nutrient availability in the TME. Notably, tumour-infiltrating immune cells typically experience metabolic stress as a result of the dysregulated metabolic activity of tumour cells, leading to impaired antitumour immune responses. Moreover, the immune checkpoints that are often exploited by tumour cells to evade immunosurveillance have emerging roles in modulating the metabolic and functional activity of T cells. Thus, repurposing of drugs targeting cancer metabolism might synergistically enhance immunotherapy via metabolic reprogramming of the TME. In addition, interventions targeting the metabolic circuits that impede antitumour immunity have been developed, with several clinical trials underway. Herein, we discuss how these metabolic circuits regulate antitumour immunity and the possible approaches to targeting these pathways in the context of anticancer immunotherapy. We also describe hypothetical combination treatments that could be used to better unleash the potential of adoptive cell therapies by enhancing T cell metabolism.
Mots-clé
Antineoplastic Agents/pharmacology, Antineoplastic Agents/therapeutic use, Combined Modality Therapy, Drug Repositioning, Drug Synergism, Humans, Immunotherapy/methods, Metabolic Networks and Pathways/drug effects, Neoplasms/drug therapy, Neoplasms/immunology, Tumor Microenvironment/drug effects
Pubmed
Web of science
Open Access
Oui
Création de la notice
03/04/2019 16:26
Dernière modification de la notice
21/08/2019 6:36
Données d'usage